Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Amphastar Pharmaceuticals manufactures and markets generic injectable pharmaceuticals, respiratory products (including albuterol inhalers), and biosimilar products, with manufacturing facilities in California and China. The company specializes in technically complex sterile injectables where regulatory barriers and manufacturing expertise create competitive moats, serving hospital and retail pharmacy channels primarily in the US market. Stock performance is driven by new product approvals (particularly biosimilars), pricing dynamics in the generic drug market, and manufacturing efficiency at its vertically-integrated facilities.
Amphastar generates revenue through a vertically-integrated manufacturing model that produces technically complex sterile injectables and respiratory products where high regulatory barriers limit competition. The company benefits from first-to-file opportunities on generic drugs (180-day exclusivity periods), long-term supply contracts with hospital systems and GPOs, and pricing power on products with limited competition. Gross margins of 51% reflect manufacturing efficiency from in-house API production and formulation capabilities. The biosimilar pipeline represents a strategic shift toward higher-margin, longer lifecycle products compared to traditional generics which face continuous pricing pressure.
FDA approval announcements for new ANDA filings and biosimilar candidates - particularly high-value products with limited competition
Biosimilar launch progress and market share capture for Fylnetra (Neulasta biosimilar) and pipeline products
Generic drug pricing trends - particularly for core hospital injectable portfolio where pricing erosion or stabilization impacts margins
Manufacturing capacity expansion updates and facility inspection outcomes (FDA Form 483s or warning letters)
Competitive dynamics on key products - new entrants or supply disruptions affecting market share
Ongoing generic drug pricing pressure from consolidation among pharmacy benefit managers and hospital GPOs, with average annual price erosion of 5-15% on mature products requiring constant new product launches to maintain revenue growth
Regulatory risk from FDA manufacturing inspections and potential consent decrees, particularly given international manufacturing footprint in China where supply chain scrutiny has intensified
Biosimilar market adoption uncertainty as payers and providers navigate interchangeability regulations and physician acceptance remains variable compared to reference biologics
Intense competition from larger generic manufacturers (Teva, Sandoz, Hikma) with greater scale and resources for complex product development and at-risk launches
Patent litigation risk on biosimilar products where reference product manufacturers aggressively defend market exclusivity through intellectual property challenges
Vertical integration by large pharmacy chains and hospital systems into generic manufacturing, potentially disintermediating specialty manufacturers
Working capital intensity from long manufacturing cycles (6-12 months for sterile injectables) and FDA-mandated inventory requirements creating cash conversion challenges during growth phases
Capital expenditure requirements for facility expansion and compliance upgrades, though current 3.12x current ratio and minimal capex ($0.0B TTM) suggest adequate liquidity
low - Pharmaceutical demand is relatively inelastic as products address critical medical needs regardless of economic conditions. Hospital utilization may fluctuate modestly with elective procedures during recessions, but emergency and critical care drugs (core portfolio) maintain stable demand. Respiratory products see seasonal patterns but limited GDP sensitivity.
Rising interest rates have moderate negative impact through higher financing costs for working capital (long inventory cycles for sterile manufacturing) and potential M&A activity. However, with debt/equity of 0.85 and strong cash generation (13% FCF yield), balance sheet impact is manageable. Valuation multiples may compress as investors rotate from growth stocks, though low current valuation (7.9x EV/EBITDA) provides cushion.
Minimal direct credit exposure. Customers are primarily large hospital systems, pharmacy chains, and wholesalers with strong credit profiles. Revenue is not dependent on consumer credit availability. Working capital requirements are driven by manufacturing lead times rather than customer financing.
value - The stock trades at attractive valuation multiples (7.9x EV/EBITDA, 1.8x P/S) relative to specialty pharma peers, with strong cash generation (13% FCF yield) appealing to value investors seeking undervalued healthcare exposure. Modest growth profile (13.6% revenue growth, 16% net income growth) and limited dividend yield suggest this is not a pure growth or income play, but rather a value opportunity with potential re-rating catalysts from biosimilar success.
moderate-to-high - Small-cap pharmaceutical stocks exhibit elevated volatility from binary FDA approval events, competitive product launches, and pricing dynamics. Recent performance shows 10.7% gain over 3 months but -6.8% over 1 year, reflecting event-driven volatility. Beta likely in 1.2-1.5 range given healthcare sector exposure and small-cap characteristics.
